Corona Remedies made a remarkable debut on the stock market, opening with a significant premium. The company’s Rs 655-crore IPO was massively oversubscribed, attracting strong interest from institutional and retail investors alike. This robust demand reflects confidence in Corona Remedies’ solid financial performance, strategic focus on key healthcare areas, and promising earnings potential.
Related Posts
Maharashtra Pawar play: NCP factions eyeing February merger?
Ajit Pawar’s untimely death in a plane crash has reignited talks of reuniting the NCP factions. Sources indicate merger talks were advanced, with Ajit Pawar […]
NPCI on ‘longest’ UPI outage: ‘The issue was caused by…’
India’s UPI experienced a five-hour outage due to banks excessively checking transaction statuses, overwhelming the system. NPCI’s investigation revealed the absence of a transaction status […]
Varma row: Ignoring RS notice illegal, says Congress; ‘petty mindset’
Congress has criticized BJP’s decision to prioritize the Lok Sabha notice regarding Justice Yashwant Varma over the Rajya Sabha notice, alleging it stems from insecurity […]